分子标志物在三阴性乳腺癌诊疗中的研究进展  

Research progress of molecular markers in the diagnosis and treatment of triple-negative breast cancer

作　　者：宁静 程光惠[1] 何明远[1] 武宁[1] NING Jing;CHENG Guanghui;HE Mingyuan;WU Ning(Department of Radiation Oncology,China-Japan Union Hospitalof Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院放射治疗科,吉林长春130033

出　　处：《中国实验诊断学》2025年第1期101-109,共9页Chinese Journal of Laboratory Diagnosis

基　　金：国家自然科学基金项目(81201737);吉林省科技发展计划资助项目(20200201524JC);吉林省教育厅科学研究项目(JJKH20211196KJ);吉林大学技术开发(委托)项目(2023220103000073);吉林省财政厅卫生科研人才专项项目(2024SCZ66)。

摘　　要：三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种高度异质性且侵袭性强的乳腺癌亚型,缺乏雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体-2(human epidermal growth factor receptor 2,HER-2)的表达,传统的激素治疗和HER-2靶向治疗对其无效,导致临床治疗选择有限。近年来,分子标志物在TNBC的诊断、预后和个性化治疗上显现出重要作用。通过深入研究这些分子标志物,未来有望开发出更为有效的诊疗方法,改善TNBC患者的预后。本文综述了近年来TNBC中主要分子标志物的研究进展及其在临床诊疗中的潜在应用,为进一步的研究和治疗提供理论基础。Triple-negative breast cancer(TNBC)is a highly heterogeneous and aggressive subtype of breast cancer,characterized by the lack of expression of estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2(HER-2)receptor.As a result,traditional hormone therapy and HER-2targeted therapy are ineffective,leading to limited clinical treatment options.In recent years,molecular markers have shown significant roles in the diagnosis,prognosis,and personalized treatment of TNBC.In-depth research into these molecular markers holds the promise of developing more effective diagnostic and therapeutic approaches in the future,improving the prognosis for TNBC patients.This review summarizes the recent research progress on major molecular markers in TNBC and their potential clinical applications,providing a theoretical foundation for further research and treatment.

关 键 词：三阴性乳腺癌 分子标志物 个性化治疗 

分 类 号：R73[医药卫生—肿瘤]